Adcendo

📍 Frederiksberg, Denmark🗓 Founded 2017👥 61 employees💰 Last funded Apr 2021
Biotechnology Research🌐 adcendo.com
Website LinkedIn
Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
Denmark
1
Frequently asked questions
Who invested in Adcendo?
Adcendo has 2 investors on record on gritt.io, 2 mid-stage.
When did Adcendo last raise funding?
The most recent investment in Adcendo recorded on gritt.io was in April 2021.
When was Adcendo founded?
Adcendo was founded in 2017.
What industry is Adcendo in?
Adcendo operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Adcendo based?
Adcendo is headquartered in Frederiksberg, Denmark.